The drugmakers also said in a statement that 12,000 people involved in their Phase 3 trial experienced high levels of protection against COVID-19 six months after their second dose, with no serious safety concerns, NBC News reports.
"It is an important step to further confirm the strong efficacy and good safety data we have seen so far," said Ugur Sahin, CEO and cofounder of BioNTech.
Full coverage of the COVID-19 outbreak and how it impacts you
"These data also provide the first clinical results that a vaccine can effectively protect against currently circulating variants, a critical factor to reach herd immunity and end this pandemic for the global population."
Read the full story on NBCNews.com